Alnylam Pharmaceuticals Q3 adjusted net income $2,241.91 million
ALNY•Alnylam Pharmaceuticals reported third-quarter adjusted net income of $2,241.91 million and adjusted EPS of $16.26, compared with an IBES estimate of $1.62. The company said it is on track to achieve its 2026 financial guidance.
1. Quarterly results
Alnylam Pharmaceuticals reported third-quarter net income of $2,167.335 million and adjusted net income of $2,241.91 million. Operating income was $345.798 million, while adjusted operating income was $424.916 million.
2. EPS and outlook
Adjusted earnings per share were $16.26, compared with an IBES estimate of $1.62. The company said it is on track to achieve its 2026 financial guidance.
